Health AI Central
Share:
Peer-Reviewed Publication
Phys Ther2025;105(6)June 2, 2025Journal Article

Transforming Care: Implications of Glucagon Like Peptide-1 Receptor Agonists on Physical Therapist Practice.

Julie Mulcahy1, Anna DeLaRosby2, Todd Norwood1
1Clinical MSK, Omada Health, San Francisco, CA, United States.
2Physera Physical Therapy Group, San Mateo, CA, United States.
PubMed PMC DOI PDF

Abstract

The goal of this perspective is to bring awareness to the prevalence of glucagon-like peptide 1 receptor agonist (GLP-1 agonist) use, medication side effects, intervention considerations, and the role of the physical therapist in supporting their patients in their health journey when taking these medications. Management of obesity and diabetes is undergoing significant change with the increasing p…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.